Rigel Pharmaceuticals, Inc. (RIGL) is around the top of the Biotechnology industry according to InvestorsObserver. RIGL received an overall rating of 50, which means that it scores higher than 50 percent of all stocks. Rigel Pharmaceuticals, Inc. also achieved a score of 83 in the Biotechnology industry, putting it above 83 percent of Biotechnology stocks. Biotechnology is ranked 113 out of the 148 industries.
What do These Ratings Mean?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 50 would rank higher than 50 percent of all stocks.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Rigel Pharmaceuticals, Inc. Stock Today?
Rigel Pharmaceuticals, Inc. (RIGL) stock is up 17.39% while the S&P 500 is down -1.39% as of 1:14 PM on Wednesday, May 12. RIGL is higher by $0.56 from the previous closing price of $3.22 on volume of 8,345,176 shares. Over the past year the S&P 500 is higher by 42.65% while RIGL is higher by 100.00%. RIGL lost -$0.08 per share the over the last 12 months.